GLP-1 Medicines and Muscle Loss: Protecting Lean Mass
Updated 13th September 2026
Somewhere around month three, people start asking a question that sounds vain and is actually sensible: is what I am losing the right kind of weight?
It is a fair question, and it has an answer that is more precise than most of the internet suggests. Body composition was measured directly in a subgroup of the SURMOUNT-1 trial using dual-energy X-ray absorptiometry, and the finding is worth knowing because it applies whichever direction your instinct runs.
Weight loss is not selective. It never has been, for any method. What the evidence supports is that the proportions are fairly predictable and that some of what happens to lean mass is influenceable.
It is a fair question, and it has an answer that is more precise than most of the internet suggests. Body composition was measured directly in a subgroup of the SURMOUNT-1 trial using dual-energy X-ray absorptiometry, and the finding is worth knowing because it applies whichever direction your instinct runs.
Weight loss is not selective. It never has been, for any method. What the evidence supports is that the proportions are fairly predictable and that some of what happens to lean mass is influenceable.
Losing weight means losing some lean mass
This is true of weight loss in general, not of these medicines in particular, and the trial data makes that unusually clear.
In the SURMOUNT-1 body composition substudy, 160 participants were scanned at baseline and at week 72, 124 on tirzepatide and 36 on placebo.1 Over that period, in the tirzepatide group, body weight fell by 21.3%, fat mass by 33.9% and lean mass by 10.9%. In the placebo group the corresponding reductions were 5.3%, 8.2% and 2.6%.1
Those are trial figures for a defined study population followed for 72 weeks, not a forecast for any individual. What matters more than the absolute numbers is the ratio the authors report: "approximately 75% was fat mass and 25% was lean mass for both tirzepatide and placebo", a proportion that held across subgroups by sex, age and by how much weight people lost.1
Read that last part carefully, because it is the most useful line in the paper. The same roughly three-to-one split appeared in the placebo group. The medicine changed how much total weight came off; it did not appear to change the composition of what came off. That reframes the question from "is this medicine costing me muscle" to "how do I influence body composition during any substantial weight loss".
A separate review in Diabetes Care puts the scale of the lean mass change in blunter terms, describing rapid and significant loss of lean mass of around 10%, or about 6 kg, across the incretin-based medicines, and comparing that to a decade or more of ageing.2 That comparison is the authors' framing rather than a UK regulatory statement, and it is worth noting the paper's purpose was to argue for resistance exercise alongside treatment.
Considering treatment for weight management? You can start an assessment with a Cloud Pharmacy clinician, who will review your medical history and confirm whether treatment is appropriate.
In the SURMOUNT-1 body composition substudy, 160 participants were scanned at baseline and at week 72, 124 on tirzepatide and 36 on placebo.1 Over that period, in the tirzepatide group, body weight fell by 21.3%, fat mass by 33.9% and lean mass by 10.9%. In the placebo group the corresponding reductions were 5.3%, 8.2% and 2.6%.1
Those are trial figures for a defined study population followed for 72 weeks, not a forecast for any individual. What matters more than the absolute numbers is the ratio the authors report: "approximately 75% was fat mass and 25% was lean mass for both tirzepatide and placebo", a proportion that held across subgroups by sex, age and by how much weight people lost.1
Read that last part carefully, because it is the most useful line in the paper. The same roughly three-to-one split appeared in the placebo group. The medicine changed how much total weight came off; it did not appear to change the composition of what came off. That reframes the question from "is this medicine costing me muscle" to "how do I influence body composition during any substantial weight loss".
A separate review in Diabetes Care puts the scale of the lean mass change in blunter terms, describing rapid and significant loss of lean mass of around 10%, or about 6 kg, across the incretin-based medicines, and comparing that to a decade or more of ageing.2 That comparison is the authors' framing rather than a UK regulatory statement, and it is worth noting the paper's purpose was to argue for resistance exercise alongside treatment.
Considering treatment for weight management? You can start an assessment with a Cloud Pharmacy clinician, who will review your medical history and confirm whether treatment is appropriate.
Why lean mass matters beyond appearance
Three practical reasons, none of them cosmetic.
Function. Lean mass underpins strength, balance and the ability to do ordinary physical things. That matters at every age and matters more with each decade.
Energy expenditure. Lean tissue is metabolically active, so losing it reduces the calories your body uses at rest. This is one of the reasons maintaining weight loss requires more activity than achieving it did, and NICE reflects that in its figures: 45 to 60 minutes of moderate-intensity activity a day to prevent obesity, rising to 60 to 90 minutes a day for people who have lost weight and are avoiding regain.4
Longer-term risk. The Diabetes Care review frames its argument around preserving muscle mass to reduce the risk of sarcopenia and associated illness.2
There is also a measurement point worth knowing. BMI cannot distinguish between fat and lean tissue, which is why NICE asks for it to be interpreted with caution in adults with high muscle mass, and why waist-to-height ratio is now used alongside it: healthy at 0.4 to 0.49, increased at 0.5 to 0.59, high at 0.6 or above, applicable across body compositions including adults with high muscle mass.8 If you are working on body composition rather than only on weight, the tape measure tells you more than the scales.
Function. Lean mass underpins strength, balance and the ability to do ordinary physical things. That matters at every age and matters more with each decade.
Energy expenditure. Lean tissue is metabolically active, so losing it reduces the calories your body uses at rest. This is one of the reasons maintaining weight loss requires more activity than achieving it did, and NICE reflects that in its figures: 45 to 60 minutes of moderate-intensity activity a day to prevent obesity, rising to 60 to 90 minutes a day for people who have lost weight and are avoiding regain.4
Longer-term risk. The Diabetes Care review frames its argument around preserving muscle mass to reduce the risk of sarcopenia and associated illness.2
There is also a measurement point worth knowing. BMI cannot distinguish between fat and lean tissue, which is why NICE asks for it to be interpreted with caution in adults with high muscle mass, and why waist-to-height ratio is now used alongside it: healthy at 0.4 to 0.49, increased at 0.5 to 0.59, high at 0.6 or above, applicable across body compositions including adults with high muscle mass.8 If you are working on body composition rather than only on weight, the tape measure tells you more than the scales.
What the evidence suggests about resistance exercise
This is where the most actionable finding sits.
The Diabetes Care review reports that supervised resistance exercise training interventions lasting more than 10 weeks can produce large increases in lean mass of around 3 kg, and proposes resistance training as a way to offset lean mass losses during incretin-based therapy.2
Three qualifications belong with that figure, and stating them is more useful than the headline.
The 3 kg figure comes from supervised resistance training interventions in general, not from studies of people taking these medicines. The review is making a case that the two should be combined, not reporting a completed trial of the combination. Its framing is a question: can resistance exercise optimise changes in body composition.2
The duration matters. More than 10 weeks is the threshold the review identifies, which rules out expecting much from a few sessions.
And "supervised" is doing work in that sentence. The interventions producing those results involved structured programmes rather than occasional independent effort.
NICE's own recommendations are broader and worth reading alongside. Build up to recommended activity levels using a managed approach with agreed goals; use activities that fit into everyday life such as brisk walking, gardening or cycling, alongside supervised exercise programmes or other activities such as swimming, step targets or stair climbing; and take current physical fitness and ability into account for all activities.4 NICE also asks that staff leading supervised physical activity sessions are appropriately qualified and insured, for example a physiotherapist or a practitioner member of the Chartered Institute for the Management of Sport and Physical Activity.4
That last detail is practically useful: if you are looking for supervised resistance training, professional qualification is a reasonable thing to ask about.
The broader point NICE makes applies here too. Increase physical activity even if it does not change your weight, because of the other health benefits it brings.4 For lean mass specifically, weight is the wrong scoreboard anyway.
The Diabetes Care review reports that supervised resistance exercise training interventions lasting more than 10 weeks can produce large increases in lean mass of around 3 kg, and proposes resistance training as a way to offset lean mass losses during incretin-based therapy.2
Three qualifications belong with that figure, and stating them is more useful than the headline.
The 3 kg figure comes from supervised resistance training interventions in general, not from studies of people taking these medicines. The review is making a case that the two should be combined, not reporting a completed trial of the combination. Its framing is a question: can resistance exercise optimise changes in body composition.2
The duration matters. More than 10 weeks is the threshold the review identifies, which rules out expecting much from a few sessions.
And "supervised" is doing work in that sentence. The interventions producing those results involved structured programmes rather than occasional independent effort.
NICE's own recommendations are broader and worth reading alongside. Build up to recommended activity levels using a managed approach with agreed goals; use activities that fit into everyday life such as brisk walking, gardening or cycling, alongside supervised exercise programmes or other activities such as swimming, step targets or stair climbing; and take current physical fitness and ability into account for all activities.4 NICE also asks that staff leading supervised physical activity sessions are appropriately qualified and insured, for example a physiotherapist or a practitioner member of the Chartered Institute for the Management of Sport and Physical Activity.4
That last detail is practically useful: if you are looking for supervised resistance training, professional qualification is a reasonable thing to ask about.
The broader point NICE makes applies here too. Increase physical activity even if it does not change your weight, because of the other health benefits it brings.4 For lean mass specifically, weight is the wrong scoreboard anyway.
Nutrition on a reduced intake
Appetite reduction is the therapeutic effect, and it creates a specific problem: nutritional requirements do not fall in proportion to how much you feel like eating.
The Eatwell Guide is the reference for what should be in a smaller intake: fruit and vegetables and starchy foods each making up just over a third of what you eat, protein from beans, pulses, fish, eggs and meat, at least two portions of fish a week including one oily such as salmon, sardines or mackerel, lower-fat and lower-sugar dairy or alternatives, and 6 to 8 glasses of fluid a day.6 Beans and pulses are specifically noted as low-fat sources of protein and fibre.6
NICE adds a point that applies directly when intake drops a long way. Where there is concern about the adequacy of micronutrient intake, consider a supplement providing the reference nutrient intake for all vitamins and minerals, particularly for older people who may be at risk of malnutrition and young people who need vitamins and minerals for growth and development.5
On protein specifically, there is a gap worth being honest about. The approved UK sources this guide draws on describe protein food groups and balanced-diet proportions; they do not set a protein target in grams for someone losing weight on these medicines. Rather than invent a figure, the practical position is that protein should be a deliberate part of each meal rather than an afterthought, and that if you are eating substantially less than before, a discussion with your prescriber, pharmacist or a registered dietitian about whether your intake is adequate is a reasonable use of an appointment. NICE asks that dietary approaches maintaining an energy deficit are offered with support from an appropriately trained professional such as a registered dietitian or registered nutritionist, and with follow-up.4
Rate matters too. The NHS advises steady change of 0.5 to 1 kg, or 1 to 2 lb, a week.7 Faster loss gives lean tissue less opportunity to be preserved.
The Eatwell Guide is the reference for what should be in a smaller intake: fruit and vegetables and starchy foods each making up just over a third of what you eat, protein from beans, pulses, fish, eggs and meat, at least two portions of fish a week including one oily such as salmon, sardines or mackerel, lower-fat and lower-sugar dairy or alternatives, and 6 to 8 glasses of fluid a day.6 Beans and pulses are specifically noted as low-fat sources of protein and fibre.6
NICE adds a point that applies directly when intake drops a long way. Where there is concern about the adequacy of micronutrient intake, consider a supplement providing the reference nutrient intake for all vitamins and minerals, particularly for older people who may be at risk of malnutrition and young people who need vitamins and minerals for growth and development.5
On protein specifically, there is a gap worth being honest about. The approved UK sources this guide draws on describe protein food groups and balanced-diet proportions; they do not set a protein target in grams for someone losing weight on these medicines. Rather than invent a figure, the practical position is that protein should be a deliberate part of each meal rather than an afterthought, and that if you are eating substantially less than before, a discussion with your prescriber, pharmacist or a registered dietitian about whether your intake is adequate is a reasonable use of an appointment. NICE asks that dietary approaches maintaining an energy deficit are offered with support from an appropriately trained professional such as a registered dietitian or registered nutritionist, and with follow-up.4
Rate matters too. The NHS advises steady change of 0.5 to 1 kg, or 1 to 2 lb, a week.7 Faster loss gives lean tissue less opportunity to be preserved.
What to raise with your clinician
Bring this up as its own item rather than hoping it comes up.
Useful things to ask: whether your rate of weight change is where it should be; whether your protein and overall nutritional intake look adequate given how much less you are eating; whether a vitamin and mineral supplement should be considered; whether there is a route to supervised strength training locally, including through any weight management service you are under; and whether anything about your other conditions changes what exercise is appropriate.
Worth flagging without being asked: any new weakness, difficulty with stairs or with rising from a chair, or falls. Those are symptoms rather than fitness observations.
And keep the review cycle in view. For tirzepatide, NICE frames a decision at six months on the highest tolerated dose, weighing the benefits and risks for that person.3 Body composition is a legitimate part of that discussion rather than a side issue.
Useful things to ask: whether your rate of weight change is where it should be; whether your protein and overall nutritional intake look adequate given how much less you are eating; whether a vitamin and mineral supplement should be considered; whether there is a route to supervised strength training locally, including through any weight management service you are under; and whether anything about your other conditions changes what exercise is appropriate.
Worth flagging without being asked: any new weakness, difficulty with stairs or with rising from a chair, or falls. Those are symptoms rather than fitness observations.
And keep the review cycle in view. For tirzepatide, NICE frames a decision at six months on the highest tolerated dose, weighing the benefits and risks for that person.3 Body composition is a legitimate part of that discussion rather than a side issue.
Common questions
Am I losing more muscle than I would on a diet?
The SURMOUNT-1 substudy found approximately 75% of the weight lost was fat mass and 25% lean mass in both the tirzepatide group and the placebo group, and that this proportion held across subgroups.1 On that measure the composition of the loss was similar; what differed was the total amount. Since the amount was larger on treatment, the absolute lean mass change was larger too: 10.9% versus 2.6% over 72 weeks in that substudy.1Will resistance training stop lean mass loss entirely?
The evidence does not support a claim that strong. The Diabetes Care review reports that supervised resistance training over more than 10 weeks can produce increases in lean mass of around 3 kg and proposes it as a way to offset losses, framing the combination as a question rather than a settled finding.2 What is reasonable to say is that resistance training is the intervention the literature points to, and that NICE recommends increasing activity regardless of its effect on weight.4How would I know if I am losing muscle?
Not from the scales, and not reliably from BMI, which cannot distinguish fat from lean tissue.8 Functional signs are more informative in everyday life: strength in familiar tasks, stairs, getting up from a low chair. Direct measurement in the trial used DXA scanning, which is a research and clinical tool rather than something to arrange casually.1Should I be taking protein supplements?
That is a question for your prescriber, pharmacist or a dietitian rather than one this guide can answer, because the approved UK sources it draws on do not set a protein target for this situation. What NICE does support is dietary approaches offered with support from an appropriately trained professional, and considering a vitamin and mineral supplement where micronutrient adequacy is a concern.45Does this mean I should lose weight more slowly?
The NHS advises 0.5 to 1 kg a week as the target rate, which is slower than many people achieve early on these medicines.7 Rate is not entirely within your control on a titrated medicine, but it is a reasonable thing to raise at review, particularly alongside questions about nutritional adequacy.The next step
Add one specific item to your next review appointment: ask whether your rate of weight change and your current intake are adequate, and ask what strength training route is available to you, including through any weight management service you are under. In the meantime, two things you can start without waiting: make protein a deliberate part of every meal rather than whatever is left after the appetite has gone, and use a tape measure alongside the scales, since waist-to-height ratio tells you something BMI cannot.8 If you are not currently under a service and want to understand your options, you can start an assessment with a Cloud Pharmacy clinician.
Important information
This guide is for general information only and does not constitute medical advice, diagnosis or treatment. The information here describes general clinical context based on UK regulatory sources cited above; it is not a recommendation for any specific medicine or treatment, which can only be made by a prescriber following individual assessment.
If you are considering treatment, speak to your GP or pharmacist, or arrange a consultation with a Cloud Pharmacy clinician. Prescription-only medicines are issued only after clinical assessment and where appropriate.
If you experience side effects from any medicine, you can report them through the Yellow Card scheme at yellowcard.mhra.gov.uk.
References used in this guide:
If you are considering treatment, speak to your GP or pharmacist, or arrange a consultation with a Cloud Pharmacy clinician. Prescription-only medicines are issued only after clinical assessment and where appropriate.
If you experience side effects from any medicine, you can report them through the Yellow Card scheme at yellowcard.mhra.gov.uk.
References used in this guide:
- Source: PubMed (pubmed.ncbi.nlm.nih.gov), PMID 39996356.
- Source: PubMed (pubmed.ncbi.nlm.nih.gov), PMID 38687506.
- Source: electronic Medicines Compendium (medicines.org.uk).
- Contains public sector information licensed under the Open Government Licence v3.0.
- Source: NHS Eatwell Guide (nhs.uk).
- Source: NHS website (nhs.uk).
References
- Body composition changes during weight reduction with tirzepatide in SURMOUNT-1, Diabetes Obes Metab 2025, PMID 39996356
- Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition? Diabetes Care 2024, PMID 38687506
- Mounjaro (tirzepatide) SmPC
- NICE NG246, physical activity and dietary approaches
- NICE NG246, medicines and surgery
- NHS Eatwell Guide
- NHS, Obesity, treatment
- NICE NG246, identifying and assessing overweight, obesity and central adiposity
Fahmida Kadir
Deputy Superintendent Pharmacist
Start Your Free Consultation
Complete our online questionnaire so our clinical team can check eligibility for the desired treatment.
- Takes less than 5 minutes to complete
- Reviewed by our UK-based medical team
- Approved treatments dispatched same day (before 3pm)
Review Date13 September 2026
Next Review13 September 2027
Published On13 September 2026
Last Update13 September 2026
Related guides
Am I Eligible
Am I Eligible for Mounjaro?
What you can establish yourself before a consultation, what only a clinician can determine, and why a service that approves you instantly has...
Read more ›Age Limits for
Age Limits for Weight Loss Medication in the UK
What each UK weight management medicine says about minimum age, adolescents, older adults and where the data runs out, drawn from the SmPCs and...
Read more ›GLP-1 vs Dual
GLP-1 vs Dual GIP/GLP-1 Medicines Explained
What separates a GLP-1 receptor agonist from a dual GIP/GLP-1 agonist, how the licensed criteria and NHS access differ, and how a prescriber...
Read more ›Related treatments
Clinically proven, pharmacist-reviewed weight loss treatments.
